Treatment of Subarachnoid Hemorrhage in the Neurocritical Care Unit

  • Christopher M. Jackson
  • Justin M. Caplan
  • Judy Huang
  • Rafael J. TamargoEmail author
Part of the Current Clinical Neurology book series (CCNEU)


Aneurysmal subarachnoid hemorrhage (aSAH) is a neurological emergency with a high mortality rate in the acute period and a significant risk of mortality or permanent injury in the weeks following aneurysm rupture. In addition to neurologic injury, the systemic sequelae of aSAH impact multiple organ systems, confounding the treatment of vasospasm and delayed cerebral ischemia. Given the complexity of this disease process, aSAH patients should be cared for by multidisciplinary teams at high-volume centers in dedicated neurocritical care units. Although there is a paucity of high-quality evidence to guide management of aSAH, protocols that reflect the evolving risks these patients face in the hours, days, and weeks following aneurysm rupture can maximize the potential for neurologic recovery. This chapter is intended to provide an overview of these risks and serve as a guide for developing such protocols based on the best available evidence.


Subarachnoid hemorrhage Early brain injury Hydrocephalus Delayed cerebral ischemia Vasospasm Neurogenic stress cardiomyopathy Neurogenic pulmonary edema Cerebral salt wasting 


  1. 1.
    Incidence of subarachnoid haemorrhage: a systematic review with emphasis on region, age, gender and time trends. 2007;78(12):1365–72. Available from:
  2. 2.
    A multinational comparison of subarachnoid hemorrhage epidemiology in the WHO MONICA stroke study. 2000;31(5):1054–61. Available from:
  3. 3.
    The epidemiology of admissions of nontraumatic subarachnoid hemorrhage in the United States. 2013;73(2):217–23. Available from:
  4. 4.
    Subarachnoid hemorrhage incidence among whites, blacks and caribbean hispanics: the Northern Manhattan Study. 2006;26(3):147–50. Available from:
  5. 5.
    Characteristics of nontraumatic subarachnoid hemorrhage in the United States in 2003. 2007;61(6):1131–8. Available from:
  6. 6.
    Sudden death from aneurysmal subarachnoid hemorrhage. 1995;45(5):871–4. Available from:
  7. 7.
    Incidence, case-fatalities and 10-year survival of subarachnoid hemorrhage in a population-based registry. 2009;62(3):155–60. Available from:
  8. 8.
    Differences in aneurysm and patient characteristics between cohorts of finnish and dutch patients with subarachnoid hemorrhage: time trends between 1986 and 2005. 2008;39(12):3166–71. Available from:
  9. 9.
    Gender-related differences in aneurysmal subarachnoid hemorrhage: A hospital based study. 2017;157:82–7. Available from:
  10. 10.
    Gender and ethnic differences in subarachnoid hemorrhage. 2008;71(10):731–5. Available from:
  11. 11.
    Menstrual and reproductive factors for subarachnoid hemorrhage risk in women: a case-control study in nagoya, Japan. 2001;32(12):2841–4. Available from:
  12. 12.
    Sex, smoking, and risk for subarachnoid hemorrhage. 2016;47(8):1975–81. Available from:
  13. 13.
    Sex differences in risk factors for aneurysmal subarachnoid hemorrhage: a cohort study. 2011;76(7):637–43. Available from:
  14. 14.
    The importance of cerebral aneurysms in childhood hemorrhagic stroke: a population-based study. 2009;40(2):400–5. Available from:
  15. 15.
    Socioeconomic disadvantage is associated with a higher incidence of aneurysmal subarachnoid hemorrhage. 2018;27(3):660–8. Available from:
  16. 16.
    Incidence and risks of subarachnoid hemorrhage in China. 2013;44(10):2891–3. Available from:
  17. 17.
    Socioeconomic inequalities in the incidence, mortality and prognosis of subarachnoid hemorrhage: the FINMONICA Stroke Register. 2001;12(1):7–13. Available from:
  18. 18.
    Greater rupture risk for familial as compared to sporadic unruptured intracranial aneurysms. 2009;40(6):1952–7. Available from:
  19. 19.
    Guidelines for the management of aneurysmal subarachnoid hemorrhage: a statement for healthcare professionals from a Special Writing Group of the Stroke Council, American Heart Association. 2009;40(3):994–1025. Available from:
  20. 20.
    Intracranial aneurysm–associated single-nucleotide polymorphisms alter regulatory DNA in the human circle of willis. 2018;49(2):447–53. Available from:
  21. 21.
    Identification of six polymorphisms as novel susceptibility loci for ischemic or hemorrhagic stroke by exome-wide association studies. 2017;39(6):1477–91. Available from:
  22. 22.
    Risk factors for aneurysmal subarachnoid hemorrhage in a prospective population study: the HUNT Study in Norway. 2009;40(6):1958–62. Available from:
  23. 23.
    Modifiable risk factors for aneurysmal subarachnoid hemorrhage. 2013;44(12):3607–12. Available from:
  24. 24.
    Trigger factors and their attributable risk for rupture of intracranial aneurysms: a case-crossover study. 2011;42(7):1878–82. Available from:
  25. 25.
    Risk factors for aneurysmal subarachnoid hemorrhage in a prospective population study: the HUNT Study in Norway. 2009;40(6):1958–62. Available from:
  26. 26.
    Smoking and family history and risk of aneurysmal subarachnoid hemorrhage. 2009;72(1):69–72. Available from:
  27. 27.
    Sex, smoking, and risk for subarachnoid hemorrhage. 2016;47(8):1975–81. Available from:
  28. 28.
    Association of intracranial aneurysm rupture with smoking duration, intensity, and cessation. 2017;89(13):1408–15. Available from:
  29. 29.
    Smoking and non-smoking tobacco as risk factors in subarachnoid haemorrhage. 2006;114(1):33–7. Available from:
  30. 30.
    Risk factors for aneurysmal subarachnoid hemorrhage – BMI and serum lipids: 11-year follow-up of the HUNT and the Tromsø Study in Norway. 2011;125(6):382–8. Available from:
  31. 31.
    Intracranial aneurysms and cocaine abuse: analysis of prognostic indicators. 2000;46(5):1063–7–discussion 1067–9. Available from:
  32. 32.
    Alcohol consumption and aneurysmal subarachnoid hemorrhage. 2017;9(1):13–9. Available from:
  33. 33.
    Role of genetic polymorphisms in predicting delayed cerebral ischemia and radiographic vasospasm after aneurysmal subarachnoid hemorrhage: a meta-analysis. 2015;84(4):933–941.e2. Available from:
  34. 34.
    Unique contribution of haptoglobin and haptoglobin genotype in aneurysmal subarachnoid hemorrhage. 201831;9:529. Available from:
  35. 35.
    Haemoglobin scavenging after subarachnoid haemorrhage. Cham: Springer International Publishing; 2014. pp. 51–4. Available from:
  36. 36.
    Aneurysm formation in proinflammatory, transgenic haptoglobin 2–2 mice. 2013;72(1):70–6. Available from:
  37. 37.
    Haptoglobin phenotype predicts the development of focal and global cerebral vasospasm and may influence outcomes after aneurysmal subarachnoid hemorrhage. 2015;112(4):1155–60. Available from:
  38. 38.
    Role of inflammation (leukocyte-endothelial cell interactions) in vasospasm after subarachnoid hemorrhage. 2010;73(1):22–41. Available from:
  39. 39.
    Haptoglobin and the development of cerebral artery vasospasm after subarachnoid hemorrhage. 2006;66(5):634–40. Available from:
  40. 40.
    Study of correlation between Hp α1 expression of haptoglobin 2-1 and clinical course in aneurysmal subarachnoid hemorrhage. 2018. Available from:
  41. 41.
    Multidisciplinary management and emerging therapeutic strategies in aneurysmal subarachnoid haemorrhage. 2010;9(5):504–19. Available from:
  42. 42.
    Loss of consciousness at onset of subarachnoid hemorrhage as an important marker of early brain injury. 2016;73(1):28. Available from:
  43. 43.
    Loss of consciousness at onset of aneurysmal subarachnoid hemorrhage is associated with functional outcomes in good-grade patients. 2017;98:308–13. Available from:
  44. 44.
    Warning signs in subarachnoid hemorrhage: a cooperative study. 1991;84(4):277–81. Available from:
  45. 45.
    Prospective study of sentinel headache in aneurysmal subarachnoid haemorrhage. 1994;344(8922):590–3. Available from:
  46. 46.
    Guidelines for the management of aneurysmal subarachnoid hemorrhage: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. 2012;43(6):1711–37. Available from:
  47. 47.
    Warning leak and management outcome in aneurysmal subarachnoid hemorrhage. 1996;85(6):995–9. Available from:
  48. 48.
    Initial misdiagnosis and outcome after subarachnoid hemorrhage. 2004;291(7):866. Available from:
  49. 49.
    Diagnosing headache in the emergency department: what is more important? Being right, or not being wrong? 2008;15(12):1257–8. Available from:
  50. 50.
    Headache characteristics in subarachnoid haemorrhage and benign thunderclap headache. 1998;65(5):791–3. Available from:
  51. 51.
    Focal neurological deficit at onset of aneurysmal subarachnoid hemorrhage: frequency and causes. 2016;25(11):2644–7. Available from:
  52. 52.
    Seizures at the onset of subarachnoid haemorrhage. 1996;243(2):161–4. Available from:
  53. 53.
    Determining the sensitivity of computed tomography scanning in early detection of subarachnoid hemorrhage. 2010;66(5):900–2–discussion 903. Available from:
  54. 54.
    Spontaneous subarachnoid hemorrhage: a systematic review and meta-analysis describing the diagnostic accuracy of history, physical examination, imaging, and lumbar puncture with an exploration of test thresholds. 2nd ed. 2016;23(9):963–1003. Available from:
  55. 55.
    Limitations of magnetic resonance imaging and magnetic resonance angiography in the diagnosis of intracranial aneurysms. 2008;63(1):29–35. Available from:
  56. 56.
    Caseload as a factor for outcome in aneurysmal subarachnoid hemorrhage: a systematic review and meta-analysis. 2014;120(3):605–11. Available from:
  57. 57.
    Mortality rates after subarachnoid hemorrhage: variations according to hospital case volume in 18 states. 2003;99(5):810–7. Available from:
  58. 58.
    Incidence and significance of early aneurysmal rebleeding before neurosurgical or neurological management. 2001;32(5):1176–80. Available from:
  59. 59.
    Risk factors related to aneurysmal rebleeding. 2011;76(3–4):292–8. Available from:
  60. 60.
    A sustained systemic inflammatory response syndrome is associated with shunt-dependent hydrocephalus after aneurysmal subarachnoid hemorrhage. 2018;23:1–8. Available from:
  61. 61.
    Predicting factors for shunt-dependent hydrocephalus in patients with aneurysmal subarachnoid hemorrhage. 2018;160(7):1407–13. Available from:
  62. 62.
    Shunt-dependent hydrocephalus after rupture of intracranial aneurysms: a prospective study of the influence of treatment modality. 2nd ed. 2004;101(3):402–7. Available from:
  63. 63.
    Shunt-dependent hydrocephalus after aneurysmal subarachnoid hemorrhage: predictors and long-term functional outcomes. 2017;41(8):e519. Available from:
  64. 64.
    Predictors of shunt-dependent hydrocephalus after aneurysmal subarachnoid hemorrhage? A systematic review and meta-analysis. 2017;106:844–6. Available from:
  65. 65.
    Predictors of shunt-dependent hydrocephalus following aneurysmal subarachnoid hemorrhage. 2016;86:226–32. Available from:
  66. 66.
    External ventricular drainage response in poor grade aneurysmal subarachnoid hemorrhage: effect on preoperative grading and prognosis. 2007;6(3):174–80. Available from:
  67. 67.
    Comparison of rapid and gradual weaning from external ventricular drainage in patients with aneurysmal subarachnoid hemorrhage: a prospective randomized trial. 2004;100(2):225–9. Available from:
  68. 68.
    Predictors of shunt dependency after aneurysmal subarachnoid hemorrhage: results of a single-center clinical trial. 2014;156(11):2059–69. Available from:
  69. 69.
    Management of external ventricular drains after subarachnoid hemorrhage: a multi-institutional survey. 2016;26(3):356–61. Available from:
  70. 70.
    Risk of rebleeding after treatment of acute hydrocephalus in patients with aneurysmal subarachnoid hemorrhage. 2006;38(1):96–9. Available from:
  71. 71.
    Preoperative ventriculostomy and rebleeding after aneurysmal subarachnoid hemorrhage. 2002;97(5):1042–4. Available from:
  72. 72.
    Lumbar drainage for subarachnoid hemorrhage: technical considerations and safety analysis. 2007;7(1):3–9. Available from:
  73. 73.
    The risk of rebleeding after external lumbar drainage in patients with untreated ruptured cerebral aneurysms. 2005;147(11):1157–62. Available from:
  74. 74.
    The safety of intraoperative lumbar subarachnoid drainage for acutely ruptured intracranial aneurysm: technical note. 1997;48(4):338–42–discussion 342–4. Available from:
  75. 75.
    Improved outcome in high-grade aneurysmal subarachnoid hemorrhage by enhancement of endogenous clearance of cisternal blood clots: a prospective study that demonstrates the role of lamina terminalis fenestration combined with modern microsurgical cisternal blood evacuation. 2007;50(6):355–62. Available from:
  76. 76.
    Efficacy of lamina terminalis fenestration in reducing shunt-dependent hydrocephalus following aneurysmal subarachnoid hemorrhage: a systematic review. 2nd ed. 2009;111(1):147–54. Available from:
  77. 77.
    Microsurgical fenestration of the lamina terminalis reduces the incidence of shunt-dependent hydrocephalus after aneurysmal subarachnoid hemorrhage. 2002;51(6):1403–12–discussion 1412–3. Available from:
  78. 78.
    Reduction of shunt dependency rates following aneurysmal subarachnoid hemorrhage by tandem fenestration of the lamina terminalis and membrane of Liliequist during microsurgical aneurysm repair. 2017;60:1–7. Available from:
  79. 79.
    Predictors and impact of aneurysm rebleeding after subarachnoid hemorrhage. 2005;62(3):410. Available from:
  80. 80.
    Rebleeding after aneurysmal subarachnoid hemorrhage. 2011;15(2):241–6. Available from:
  81. 81.
    The international cooperative study on the timing of aneurysm surgery. 1990;73(1):37–47. Available from:
  82. 82.
    Aneurysmal subarachnoid hemorrhage. 2018;29(2):255–62. Available from:
  83. 83.
    Immediate administration of tranexamic acid and reduced incidence of early rebleeding after aneurysmal subarachnoid hemorrhage: a prospective randomized study. 2002;97(4):771–8. Available from:
  84. 84.
    Impact of a protocol for acute antifibrinolytic therapy on aneurysm rebleeding after subarachnoid hemorrhage. 2008;39(9):2617–21. Available from:
  85. 85.
    Critical care management of patients following aneurysmal subarachnoid hemorrhage: recommendations from the Neurocritical Care Society’s Multidisciplinary Consensus conference. 2011;15(2):211–40. Available from:
  86. 86.
    Prognostic value of premorbid hypertension and neurological status in aneurysmal subarachnoid hemorrhage: pooled analyses of individual patient data in the SAHIT repository. 2015;122(3):644–52. Available from:
  87. 87.
    Predictors of rehemorrhage after treatment of ruptured intracranial aneurysms: The Cerebral Aneurysm Rerupture After Treatment (CARAT) Study. 2007;39(1):120–5. Available from:
  88. 88.
    Seizures and anticonvulsants after aneurysmal subarachnoid hemorrhage. 2011;15(2):247–56. Available from:
  89. 89.
    Seizures and CNS hemorrhage. 2010;16(3):165–75. Available from:
  90. 90.
    Anticonvulsant prophylaxis in neurological surgery. 1985;17(3):510–7. Available from:
  91. 91.
    Seizures and epilepsy following aneurysmal subarachnoid hemorrhage: incidence and risk factors. 2009;46(2):93. Available from:
  92. 92.
    Predictors and clinical impact of epilepsy after subarachnoid hemorrhage. 2003;60(2):208–14. Available from:
  93. 93.
    Hypertension as a risk factor for epilepsy after aneurysmal subarachnoid hemorrhage and surgery. 1990;27(4):578–81. Available from:
  94. 94.
    Epilepsy after subarachnoid hemorrhage: the frequency of seizures after clip occlusion or coil embolization of a ruptured cerebral aneurysm. 2011;115(6):1159–68. Available from:
  95. 95.
    Association of seizure occurrence with aneurysm treatment modality in aneurysmal subarachnoid hemorrhage patients. 2018;23(5):1073. Available from:
  96. 96.
    A randomized trial of brief versus extended seizure prophylaxis after aneurysmal subarachnoid hemorrhage. 2017;28(2):169–74. Available from:
  97. 97.
    Prophylactic antiepileptics and seizure incidence following subarachnoid hemorrhage. 2016;47(7):1754–60. Available from:
  98. 98.
    Antiepileptic drugs for the primary and secondary prevention of seizures after subarachnoid haemorrhage. 2013;60(2):99. Available from:
  99. 99.
    Risk factors for in-hospital seizures and new-onset epilepsy in coil embolization of aneurysmal subarachnoid hemorrhage. 2018;115:e523–31. Available from:
  100. 100.
    Nonconvulsive status epilepticus after subarachnoid hemorrhage. 2002;51(5):1136–43–discussion 1144. Available from:
  101. 101.
    Nonconvulsive status epilepticus in patients suffering spontaneous subarachnoid hemorrhage. 2007;106(5):805–11. Available from:
  102. 102.
    Phenytoin exposure is associated with functional and cognitive disability after subarachnoid hemorrhage. 2005;36(3):583–7. Available from:
  103. 103.
    Outcome in patients with subarachnoid hemorrhage treated with antiepileptic drugs. 2007;107(2):253–60. Available from:
  104. 104.
    Cerebral arterial spasm–a clinical review. 1995;9(3):403–12. Available from:
  105. 105.
    Vasospasm versus delayed cerebral ischemia as an outcome event in clinical trials and observational studies. 2011;15(2):308–11. Available from:
  106. 106.
    Effect of cisternal and ventricular blood on risk of delayed cerebral ischemia after subarachnoid hemorrhage: the Fisher scale revisited. 2001;32(9):2012–20. Available from:
  107. 107.
    Cigarette smoking as a cause of aneurysmal subarachnoid hemorrhage and risk for vasospasm: a report of the Cooperative Aneurysm Study. 1998;89(3):405–11. Available from:
  108. 108.
    Cortical spreading ischaemia is a novel process involved in ischaemic damage in patients with aneurysmal subarachnoid haemorrhage. 2009;132(7):1866–81. Available from:
  109. 109.
    Neuroinflammation as a target for intervention in subarachnoid hemorrhage. 2018;9:21. Available from:
  110. 110.
    Endothelial cell dysfunction and injury in subarachnoid hemorrhage. 2018;173(1188–1194):732. Available from:
  111. 111.
    The clinical examination in the patient with subarachnoid hemorrhage is still the most reliable parameter for predicting pathophysiological changes. 2017;8(1):294. Available from:
  112. 112.
    Multidisciplinary management and emerging therapeutic strategies in aneurysmal subarachnoid haemorrhage. 2010;9(5):504–19. Available from:
  113. 113.
    Cerebral vasospasm diagnosis by means of angiography and blood velocity measurements. 1989;100(1–2):12–24. Available from:
  114. 114.
    Transcranial doppler for predicting delayed cerebral ischemia after subarachnoid hemorrhage. 2009;65(2):316–24. Available from:
  115. 115.
    Vasospasm on transcranial Doppler is predictive of delayed cerebral ischemia in aneurysmal subarachnoid hemorrhage: a systematic review and meta-analysis. 2016;124(5):1257–64. Available from:
  116. 116.
    Proximal arterial diameters on CT angiography and digital subtraction angiography correlate both at admission and in the vasospasm period after aneurysmal subarachnoid hemorrhage. Cham: Springer International Publishing; 2014. pp. 171–5. Available from:
  117. 117.
    CT angiography for the detection of cerebral vasospasm in patients with acute subarachnoid hemorrhage. 2000;21(6):1011–5. Available from:
  118. 118.
    Prospective evaluation of multidetector-row CT angiography for the diagnosis of vasospasm following subarachnoid hemorrhage: a comparison with digital subtraction angiography. 2008;25(1–2):144–50. Available from:
  119. 119.
    CT perfusion and delayed cerebral ischemia in aneurysmal subarachnoid hemorrhage: a systematic review and meta-analysis. 2013;34(2):200–7. Available from:
  120. 120.
    Vasospasm after subarachnoid hemorrhage: utility of perfusion CT and CT angiography on diagnosis and management. 2006;27(1):26–34. Available from:
  121. 121.
    Observations during hypervolemic hemodilution of patients with acute focal cerebral ischemia. 1982;248(22):2999–2304. Available from:
  122. 122.
    Treatment of ischemic deficits from vasospasm with intravascular volume expansion and induced arterial hypertension. 1982;11(3):337–43. Available from:
  123. 123.
    The treatment of brain ischemia with vasopressor drugs. 1972;3(2):135–40. Available from:
  124. 124.
    Relative importance of hypertension compared with hypervolemia for increasing cerebral oxygenation in patients with cerebral vasospasm after subarachnoid hemorrhage. 2005;103(6):974–81. Available from:
  125. 125.
    Effect of hypervolemic therapy on cerebral blood flow after subarachnoid hemorrhage: a randomized controlled trial. 2000;31(2):383–91. Available from:
  126. 126.
    Effect of different components of triple-H therapy on cerebral perfusion in patients with aneurysmal subarachnoid haemorrhage: a systematic review. 2010;14(1):R23. Available from:
  127. 127.
    Cerebral arterial spasm – a controlled trial of nimodipine in patients with subarachnoid hemorrhage. 1983;308(11):619–24. Available from:
  128. 128.
    Calcium antagonists for aneurysmal subarachnoid haemorrhage. 2007;308(4):619. Available from:
  129. 129.
    Intraoperative continuous cerebral microcirculation measurement in patients with aneurysmal subarachnoid hemorrhage: preliminary data on the early administration of magnesium sulfate. 2017;17(1):1365. Available from:
  130. 130.
    Intravenous magnesium sulphate for aneurysmal subarachnoid hemorrhage (IMASH): a randomized, double-blinded, placebo-controlled, multicenter phase iii trial. 2010;41(5):921–6. Available from:
  131. 131.
    Magnesium for aneurysmal subarachnoid haemorrhage (MASH-2): a randomised placebo-controlled trial. 2012;380(9836):44–9. Available from:
  132. 132.
    Early magnesium treatment after aneurysmal subarachnoid hemorrhage. 2015;46(11):3190–3. Available from:
  133. 133.
    Milrinone for the treatment of cerebral vasospasm after subarachnoid hemorrhage: report of seven cases. 2001;48(4):723–8–discussion 728–30. Available from:
  134. 134.
    Milrinone for the treatment of cerebral vasospasm after aneurysmal subarachnoid hemorrhage. 2008;39(3):893–8. Available from:
  135. 135.
    Milrinone as a rescue therapy for symptomatic refractory cerebral vasospasm in aneurysmal subarachnoid hemorrhage. 2008;11(2):165–71. Available from:
  136. 136.
    Angiographic evaluation of the effect of intra-arterial milrinone therapy in patients with vasospasm from aneurysmal subarachnoid hemorrhage. 2010;53(2):123–8. Available from:
  137. 137.
    Seeking new approaches: milrinone in the treatment of cerebral vasospasm. 2012;16(3):351–3. Available from:
  138. 138.
    Vasospasm after subarachnoid hemorrhage in haptoglobin 2–2 mice can be prevented with a glutathione peroxidase mimetic. 2010;17(9):1169–72. Available from:
  139. 139.
    Leukocyte-endothelial cell interactions in chronic vasospasm after subarachnoid hemorrhage. 2013;28(7):750–8. Available from:
  140. 140.
    Aneurysm formation in proinflammatory, transgenic haptoglobin 2–2 mice. 2013;72(1):70–6. Available from:
  141. 141.
    Endothelin-1 gene polymorphisms influence cerebrospinal fluid endothelin-1 levels following aneurysmal subarachnoid hemorrhage. 2015;17(2):185–90. Available from:
  142. 142.
    Clazosentan to overcome neurological ischemia and infarction occurring after subarachnoid hemorrhage (CONSCIOUS-1): randomized, double-blind, placebo-controlled phase 2 dose-finding trial. 2008;39(11):3015–21. Available from:
  143. 143.
    Clazosentan, an endothelin receptor antagonist, in patients with aneurysmal subarachnoid haemorrhage undergoing surgical clipping: a randomised, double-blind, placebo-controlled phase 3 trial (CONSCIOUS-2). 2011;10(7):618–25. Available from:
  144. 144.
    Randomized trial of clazosentan in patients with aneurysmal subarachnoid hemorrhage undergoing endovascular coiling. 2012;43(6):1463–9. Available from:
  145. 145.
    Simvastatin in aneurysmal subarachnoid haemorrhage (STASH): a multicentre randomised phase 3 trial. 2014;13(7):666–75. Available from:
  146. 146.
    Long-acting statin for aneurysmal subarachnoid hemorrhage: a randomized, double-blind, placebo-controlled trial. 2017;38(7):1190–8. Available from:
  147. 147.
    Results of an international survey on the investigation and endovascular management of cerebral vasospasm and delayed cerebral ischemia. 2015;83(6):1120–1. Available from:
  148. 148.
    Endovascular treatment of cerebral vasospasm: transluminal balloon angioplasty, intra-arterial papaverine, and intra-arterial nicardipine. 2005;16(3):501–16. Available from:
  149. 149.
    Brain–heart interaction. 2017;121(4):451–68. Available from:
  150. 150.
    Mechanisms in neurogenic stress cardiomyopathy after aneurysmal subarachnoid hemorrhage. 2006;5(3):243–9. Available from:
  151. 151.
    Tako-tsubo cardiomyopathy in aneurysmal subarachnoid hemorrhage: an underappreciated ventricular dysfunction. 2006;105(2):264–70. Available from:
  152. 152.
    Cardiac arrhythmias after subarachnoid hemorrhage: risk factors and impact on outcome. 2008;26(1):71–8. Available from:
  153. 153.
    Predictors of left ventricular regional wall motion abnormalities after subarachnoid hemorrhage. 2006;4(3):199–205. Available from:
  154. 154.
    Neurogenic stress cardiomyopathy after aneurysmal subarachnoid hemorrhage. 2015;83(6):880–5. Available from:
  155. 155.
    Predictors of neurocardiogenic injury after subarachnoid hemorrhage. 2004;35(2):548–51. Available from:
  156. 156.
    The serum level of brain natriuretic peptide increases in severe subarachnoid hemorrhage thereby reflecting an increase in both cardiac preload and afterload. 2014;38(4):276–83. Available from:
  157. 157.
    Multicenter prospective cohort study on volume management after subarachnoid hemorrhage: hemodynamic changes according to severity of subarachnoid hemorrhage and cerebral vasospasm. 2013;44(8):2155–61. Available from:
  158. 158.
    Plasma catecholamine profile of subarachnoid hemorrhage patients with neurogenic cardiomyopathy. 2015;57–67. Available from:
  159. 159.
    Neurocardiogenic injury in subarachnoid hemorrhage: A wide spectrum of catecholamin-mediated brain-heart interactions. 2014;21(3):220–8. Available from:
  160. 160.
    Effect of propranolol and phentolamine on myocardial necrosis after subarachnoid haemorrhage. 1978;2(6143):990–2. Available from:
  161. 161.
    Preadmission beta-blockers are associated with decreased incidence of neurogenic stunned myocardium in aneurysmal subarachnoid hemorrhage. 2013;22(5):601–7. Available from:
  162. 162.
    Une hypotension profonde associée au labétalol chez un patient qui présente des anévrysmes cérébraux et une hémorragie sous-arachnoïdienne. 2006;53(7):678–83. Available from:
  163. 163.
    Bedside use of a dual aortic balloon occlusion for the treatment of cerebral vasospasm. 2010;13(3):385–8. Available from:
  164. 164.
    Intra-aortic balloon pump counterpulsation in the setting of subarachnoid hemorrhage, cerebral vasospasm, and neurogenic stress cardiomyopathy. Case report and review of the literature 2010;13(1):101–8. Available from:
  165. 165.
    Monitoring of volume status after subarachnoid hemorrhage. 2011;15(2):270–4. Available from:
  166. 166.
    Prognostic significance of hypernatremia and hyponatremia among patients with aneurysmal subarachnoid hemorrhage. 2002;50(4):749–55–discussion 755–6. Available from:
  167. 167.
    Blood volume measurement to guide fluid therapy after aneurysmal subarachnoid hemorrhage: a prospective controlled study. 2009;40(7):2575–7. Available from:
  168. 168.
    Trends in the use of pulmonary artery catheterization in the aneurysmal subarachnoid hemorrhage population. 2016;31:133–6. Available from:
  169. 169.
    Goal-directed fluid management by bedside transpulmonary hemodynamic monitoring after subarachnoid hemorrhage ∗ supplemental material. 2007;38(12):3218–24. Available from:
  170. 170.
    Performance of bedside transpulmonary thermodilution monitoring for goal-directed hemodynamic management after subarachnoid hemorrhage ∗ supplemental data. 2009;40(7):2368–74. Available from:
  171. 171.
    Optimal range of global end-diastolic volume for fluid management after aneurysmal subarachnoid hemorrhage. 2014;42(6):1348–56. Available from:
  172. 172.
    Early intensive versus minimally invasive approach to postoperative hemodynamic management after subarachnoid hemorrhage. 2014;45(5):1280–4. Available from:
  173. 173.
    Administration of hypertonic (3%) sodium chloride/acetate in hyponatremic patients with symptomatic vasospasm following subarachnoid hemorrhage. 1999;11(3):178–84. Available from:
  174. 174.
    A randomized controlled trial of hydrocortisone against hyponatremia in patients with aneurysmal subarachnoid hemorrhage. 2007;38(8):2373–5. Available from:
  175. 175.
    Improved efficiency of hypervolemic therapy with inhibition of natriuresis by fludrocortisone in patients with aneurysmal subarachnoid hemorrhage. 3rd ed. 1999;91(6):947–52. Available from:
  176. 176.
    Effect of fludrocortisone acetate in patients with subarachnoid hemorrhage. 1989;20(9):1156–61. Available from:
  177. 177.
    Early inhibition of natriuresis suppresses symptomatic cerebral vasospasm in patients with aneurysmal subarachnoid hemorrhage. 2013;35(2):131–7. Available from:
  178. 178.
    Pulmonary complications of aneurysmal subarachnoid hemorrhage. 2003;52(5):1025–31–discussion 1031–2. Available from:
  179. 179.
    Could cardiac biomarkers predict neurogenic pulmonary edema in aneurysmal subarachnoid hemorrhage? 2017;159(4):705–12. Available from:
  180. 180.
    Neurogenic pulmonary edema and other mechanisms of impaired oxygenation after aneurysmal subarachnoid hemorrhage. 2004;1(2):157–70. Available from:
  181. 181.
    Acute lung injury in patients with subarachnoid hemorrhage: incidence, risk factors, and outcome. 2006;34(1):196–202. Available from:
  182. 182.
    Refining the association of fever with functional outcome in aneurysmal subarachnoid hemorrhage. 2016;26(1):41–7. Available from:
  183. 183.
    Fever after subarachnoid hemorrhage: risk factors and impact on outcome. 2007;68(13):1013–9. Available from:
  184. 184.
    Impact of medical complications on outcome after subarachnoid hemorrhage. 2006;34(3):617–23–quiz 624. Available from:
  185. 185.
    Predictive factors of fever after aneurysmal subarachnoid hemorrhage and its impact on delayed cerebral ischemia and clinical outcomes. 2018;114:e524–31. Available from:
  186. 186.
    Fever after aneurysmal subarachnoid hemorrhage: relation with extent of hydrocephalus and amount of extravasated blood. 2008;39(7):2141–3. Available from:
  187. 187.
    Non-infectious fever in the neurological intensive care unit: incidence, causes and predictors. 2007;78(11):1278–80. Available from:
  188. 188.
    Higher hemoglobin is associated with less cerebral infarction, poor outcome, and death after subarachnoid hemorrhage. 2006;59(4):775–80. Available from:
  189. 189.
    Distribution of hematocrit values after aneurysmal subarachnoid hemorrhage. 1998;8(3):169–70. Available from:
  190. 190.
    Higher hemoglobin is associated with improved outcome after subarachnoid hemorrhage∗. 2007;35(10):2383–9. Available from:
  191. 191.
    Blood transfusion and increased risk for vasospasm and poor outcome after subarachnoid hemorrhage. 2004;101(1):1–7. Available from:
  192. 192.
    Prospective, Randomized Trial of Higher Goal Hemoglobin after Subarachnoid Hemorrhage. 2010;13(3):313–20. Available from:
  193. 193.
    Optimum degree of hemodilution for brain protection in a canine model of focal cerebral ischemia. 1994;80(3):469–75. Available from:
  194. 194.
    Anemia after aneurysmal subarachnoid hemorrhage is associated with poor outcome and death. 2018:STROKEAHA.117.020260. Available from:
  195. 195.
    RBC transfusion improves cerebral oxygen delivery in subarachnoid hemorrhage. 2017;45(4):653–9. Available from:
  196. 196.
    Cognitive sequelae of subarachnoid hemorrhage, cerebral aneurysm treatment, and neuropsychological assessment. 2018. Available from:

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  • Christopher M. Jackson
    • 1
  • Justin M. Caplan
    • 1
  • Judy Huang
    • 1
  • Rafael J. Tamargo
    • 1
    • 2
    Email author
  1. 1.Department of Neurosurgery, Division of Cerebrovascular NeurosurgeryJohns Hopkins University School of MedicineBaltimoreUSA
  2. 2.Neurosciences Critical Care UnitThe Johns Hopkins HospitalBaltimoreUSA

Personalised recommendations